← Back to Search

ERAS and 5 Lung Protective Interventions for Hepatobiliary Surgery

N/A
Waitlist Available
Led By David Gutman, MD
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 hours
Awards & highlights

Study Summary

This trial will test whether adding extra measures to an existing surgical protocol will improve post-operative lung function.

Eligible Conditions
  • Hepatobiliary Surgery
  • Colorectal Surgery

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Inspiratory Capacity
Secondary outcome measures
Incidence of supplemental Oxygen Requirements
Oxygen Saturation (SPO2) Trends

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ERAS and 5 Lung Protective InterventionsExperimental Treatment1 Intervention
The standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions: Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height) Positive end-expiratory pressure (PEEP) 7cm H2O5 Immediately post intubation recruitment breath (30cm water for 30 seconds) Every 1 hour recruitment breath (30cm water for 30 seconds) 40% FIO2 initially - titrate up as necessary to maintain SPO2 >94%
Group II: Standard Enhanced Recovery After Surgery (ERAS) ProtocolActive Control1 Intervention
Control for this study will be the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ERAS and 5 Lung Protective Interventions
2021
N/A
~100

Find a Location

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
931 Previous Clinical Trials
7,393,936 Total Patients Enrolled
David Gutman, MDPrincipal Investigator - Medical University of South Carolina
Medical University of South Carolina

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Trial of Adding Lung Protective Strategies to Existing Enhanced Recovery After Surgery (ERAS) Protocols and Its Effects on Improving Post-Operative Lung Function
David Gutman 2021. "A Trial of Adding Lung Protective Strategies to Existing Enhanced Recovery After Surgery (ERAS) Protocols and Its Effects on Improving Post-Operative Lung Function". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04411186.
~25 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top